Opicapone

Opicapone is a third-generation COMT inhibitor approved as an adjunct therapy to levodopa for Parkinson's disease patients with motor fluctuations. By reversibly inhibiting peripheral COMT, Opicapone reduces the conversion of levodopa to 3-O-methyldopa, thereby increasing and prolonging levodopa plasma levels and improving clinical outcomes. The long-acting profile of Opicapone enables once-daily oral dosing, offering a convenient regimen compared to earlier COMT inhibitors. In preclinical studies, Opicapone demonstrated sustained COMT inhibition with ED₅₀ values below 1.4 mg/kg in rats, with effects persisting for up to 24 hours after a single dose. This prolonged activity of Opicapone translates to sustained enhancement of levodopa bioavailability and reduction of motor fluctuations, positioning it as a valuable addition to the Parkinson's disease therapeutic arsenal.

Product Parameters

Application

Opicapone is indicated for patients with Parkinson's disease (PD) as an adjunctive therapy to levodopa/carbidopa.

Usage and Dosage

The recommended dose of opicapone is 50 mg taken orally once daily at bedtime. Patients should not eat for 1 hour before and at least 1 hour after taking opicapone ONGENTYS. The recommended dose for patients with moderate hepatic impairment is 25 mg taken orally daily at bedtime; use in patients with severe hepatic impairment is avoided.

Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for Opicapone that meets the rigorous expectations of pharmaceutical research:

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity (≥99%), appearance verification, identity confirmation, and residual solvent analysis.

Full batch traceability with retention samples. From raw material procurement through synthesis and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery.

Contact Us

Looking for Opicapone to advance your Parkinson's disease research or drug development program? Cosperpharm is your trusted partner for high-quality COMT inhibitors. Contact us today to discuss your requirements and request a quote.